Drug Patents Expiring in 2024
1. Abilify patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8017615 (Pediatric) | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Dec, 2024
(4 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Pediatric Exclusivity(PED) | Aug 27, 2011 |
| New Indication(I-616) | Nov 19, 2012 |
| New Indication(I-633) | Feb 16, 2014 |
| M(M-137) | Jun 09, 2017 |
| New Indication(I-700) | Dec 12, 2017 |
| Orphan Drug Exclusivity(ODE) | Dec 12, 2021 |
| Orphan Drug Exclusivity(ODE-80) | Dec 12, 2021 |
Drugs and Companies using ARIPIPRAZOLE ingredient
Market Authorisation Date: 15 November, 2002
Treatment: NA
Dosage: TABLET; TABLET, ORALLY DISINTEGRATING
How can I launch a generic of ABILIFY before it's drug patent expiration?
More Information on Dosage
ABILIFY family patents
2. Abilify Maintena Kit patent expiration
ABILIFY MAINTENA KIT's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8722679 | OTSUKA PHARM CO LTD | Controlled release sterile injectable aripiprazole formulation and method |
Oct, 2024
(2 months from now) | |
| US7807680 | OTSUKA PHARM CO LTD | Controlled release sterile injectable aripiprazole formulation and method |
Oct, 2024
(2 months from now) | |
| US8030313 | OTSUKA PHARM CO LTD | Controlled release sterile injectable aripiprazole formulation and method |
Oct, 2024
(2 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Feb 28, 2016 |
| M(M-150) | Dec 05, 2017 |
| New Indication(I-746) | Jul 27, 2020 |
Drugs and Companies using ARIPIPRAZOLE ingredient
Market Authorisation Date: 28 February, 2013
Treatment: Treatment of schizophrenia
Dosage: FOR SUSPENSION, EXTENDED RELEASE
How can I launch a generic of ABILIFY MAINTENA KIT before it's drug patent expiration?
More Information on Dosage
ABILIFY MAINTENA KIT family patents
3. Abraxane patent
expiration
ABRAXANE's oppositions filed in EPO
ABRAXANE IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7820788 | BRISTOL-MYERS | Compositions and methods of delivery of pharmacological agents |
Oct, 2024
(3 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-658) | Oct 11, 2015 |
| New Indication(I-676) | Sep 06, 2016 |
| Orphan Drug Exclusivity(ODE) | Sep 06, 2020 |
| Orphan Drug Exclusivity(ODE-52) | Sep 06, 2020 |
| M(M-14) | Dec 06, 2022 |
| Pediatric Exclusivity(PED) | Jun 06, 2023 |
Drugs and Companies using PACLITAXEL ingredient
Market Authorisation Date: 07 January, 2005
Treatment: Treatment of pancreatic cancer
Dosage: POWDER
How can I launch a generic of ABRAXANE before it's drug patent expiration?
More Information on Dosage
ABRAXANE family patents
4. Acular Ls patent expiration
Can you believe ACULAR LS received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8541463 (Pediatric) | ABBVIE | Ketorolac tromethamine compositions for treating or preventing ocular pain |
Nov, 2024
(4 months from now) | |
|
US8207215 (Pediatric) | ABBVIE | Ketorolac tromethamine compositions for treating or preventing ocular pain |
Nov, 2024
(4 months from now) | |
|
US8377982 (Pediatric) | ABBVIE | Ketorolac tromethamine compositions for treating or preventing ocular pain |
Nov, 2024
(4 months from now) | |
Drugs and Companies using KETOROLAC TROMETHAMINE ingredient
Market Authorisation Date: 30 May, 2003
Treatment: NA
Dosage: SOLUTION/DROPS
How can I launch a generic of ACULAR LS before it's drug patent expiration?
More Information on Dosage
ACULAR LS family patents
5. Acuvail patent expiration
ACUVAIL's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8992952 | ABBVIE | Compositions for delivery of therapeutics into the eyes and methods for making and using same |
Aug, 2024
(11 days from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jul 22, 2012 |
Drugs and Companies using KETOROLAC TROMETHAMINE ingredient
Market Authorisation Date: 22 July, 2009
Treatment: NA
Dosage: SOLUTION/DROPS
How can I launch a generic of ACUVAIL before it's drug patent expiration?
More Information on Dosage
ACUVAIL family patents
6. Adasuve patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7458374 | ALEXZA PHARMS | Method and apparatus for vaporizing a compound |
Aug, 2024
(24 days from now) | |
| US7537009 | ALEXZA PHARMS | Method of forming an aerosol for inhalation delivery |
Oct, 2024
(3 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Dec 21, 2015 |
Drugs and Companies using LOXAPINE ingredient
Market Authorisation Date: 21 December, 2012
Treatment: NA
Dosage: POWDER
More Information on Dosage
ADASUVE family patents
7. Admelog Solostar patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9604009 | SANOFI-AVENTIS US | Drive mechanisms suitable for use in drug delivery devices |
Aug, 2024
(22 days from now) | |
| US9533105 | SANOFI-AVENTIS US | Drive mechanisms suitable for use in drug delivery devices |
Aug, 2024
(23 days from now) | |
| US9623189 | SANOFI-AVENTIS US | Relating to drive mechanisms suitable for use in drug delivery devices |
Aug, 2024
(25 days from now) | |
| US9561331 | SANOFI-AVENTIS US | Drive mechanisms suitable for use in drug delivery devices |
Aug, 2024
(a month from now) | |
| US8512297 | SANOFI-AVENTIS US | Pen-type injector |
Sep, 2024
(a month from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 11, 2020 |
Drugs and Companies using INSULIN LISPRO ingredient
Market Authorisation Date: 11 December, 2017
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
ADMELOG SOLOSTAR family patents
8. Airduo Digihaler patent expiration
AIRDUO DIGIHALER's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9987229 | TEVA PHARM | Process for preparing a medicament |
Sep, 2024
(a month from now) | |
| US9616024 | TEVA PHARM | Process for preparing a medicament |
Sep, 2024
(a month from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jan 27, 2020 |
| M(M-61) | Jul 09, 2024 |
| Pediatric Exclusivity(PED) | Jan 09, 2025 |
Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient
Market Authorisation Date: 12 July, 2019
Treatment: NA
Dosage: POWDER
More Information on Dosage
AIRDUO DIGIHALER family patents
9. Airduo Respiclick patent expiration
AIRDUO RESPICLICK's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9987229 | TEVA PHARM | Process for preparing a medicament |
Sep, 2024
(a month from now) | |
| US9616024 | TEVA PHARM | Process for preparing a medicament |
Sep, 2024
(a month from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jan 27, 2020 |
| M(M-61) | Jul 09, 2024 |
| Pediatric Exclusivity(PED) | Jan 09, 2025 |
Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient
Market Authorisation Date: 12 July, 2019
Treatment: NA
Dosage: POWDER
More Information on Dosage
AIRDUO RESPICLICK family patents
10. Aldara patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7696159 | BAUSCH | Treatment for basal cell carcinoma |
Apr, 2024
(3 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7696159 (Pediatric) | BAUSCH | Treatment for basal cell carcinoma |
Oct, 2024
(2 months from now) | |
Drugs and Companies using IMIQUIMOD ingredient
Market Authorisation Date: 27 February, 1997
Treatment: Works through the induction of interferon and other cytokines
Dosage: CREAM
How can I launch a generic of ALDARA before it's drug patent expiration?
More Information on Dosage
ALDARA family patents
11. Aliqopa patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7511041 | BAYER HEALTHCARE | Fused azole-pyrimidine derivatives |
May, 2024
(2 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 14, 2022 |
| Orphan Drug Exclusivity(ODE-155) | Sep 14, 2024 |
| Orphan Drug Exclusivity(ODE) | Sep 14, 2024 |
Drugs and Companies using COPANLISIB DIHYDROCHLORIDE ingredient
NCE-1 date: 14 September, 2021
Market Authorisation Date: 14 September, 2017
Treatment: NA
Dosage: POWDER
More Information on Dosage
ALIQOPA family patents
12. Aloxi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US9457021 (Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(5 days from now) | |
|
US7947725 (Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(5 days from now) | |
|
US9457020 (Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(5 days from now) | |
|
US7947724 (Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(5 days from now) | |
|
US8729094 (Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(5 days from now) | |
|
US8518981 (Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(5 days from now) | |
|
US7960424 (Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(5 days from now) | |
|
US8598219 (Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(5 days from now) | |
|
US8598218 (Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(5 days from now) | |
|
US9173942 (Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(5 days from now) | |
|
US9066980 (Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(5 days from now) | |
|
US9125905 (Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(5 days from now) | |
|
US9439854 (Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(5 days from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-684) | May 27, 2017 |
| M(M-136) | May 27, 2017 |
| Pediatric Exclusivity(PED) | Nov 27, 2017 |
Drugs and Companies using PALONOSETRON HYDROCHLORIDE ingredient
Market Authorisation Date: 29 February, 2008
Treatment: NA
Dosage: INJECTABLE
How can I launch a generic of ALOXI before it's drug patent expiration?
More Information on Dosage
ALOXI family patents
13. Altabax patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8207191 | ALMIRALL | Process, salts, composition and use |
Aug, 2024
(a month from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 12, 2012 |
Drugs and Companies using RETAPAMULIN ingredient
NCE-1 date: 13 April, 2011
Market Authorisation Date: 12 April, 2007
Treatment: Treatment of impetigo due to staphylococcus aureus or streptococcus pyogenes
Dosage: OINTMENT
More Information on Dosage
ALTABAX family patents
14. Amitiza patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7795312 | SUCAMPO PHARMA LLC | Method for treating abdominal discomfort |
Sep, 2024
(a month from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-670) | Apr 19, 2016 |
| M(M-225) | Apr 26, 2021 |
Drugs and Companies using LUBIPROSTONE ingredient
Market Authorisation Date: 29 April, 2008
Treatment: Method for treating irritable bowel syndrome and method for treating abdominal discomfort associated with irritable bowel syndrome
Dosage: CAPSULE
How can I launch a generic of AMITIZA before it's drug patent expiration?
More Information on Dosage
AMITIZA family patents
15. Ampyra patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9918973 | ACORDA | Sustained release aminopyridine composition |
Dec, 2024
(4 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 22, 2015 |
| Orphan Drug Exclusivity(ODE) | Jan 22, 2017 |
Drugs and Companies using DALFAMPRIDINE ingredient
NCE-1 date: 22 January, 2014
Market Authorisation Date: 22 January, 2010
Treatment: Improvement of walking in patients with multiple sclerosis (ms)
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of AMPYRA before it's drug patent expiration?
More Information on Dosage
AMPYRA family patents
16. Apidra Solostar patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9604009 | SANOFI AVENTIS US | Drive mechanisms suitable for use in drug delivery devices |
Aug, 2024
(22 days from now) | |
| US9533105 | SANOFI AVENTIS US | Drive mechanisms suitable for use in drug delivery devices |
Aug, 2024
(23 days from now) | |
| US9623189 | SANOFI AVENTIS US | Relating to drive mechanisms suitable for use in drug delivery devices |
Aug, 2024
(25 days from now) | |
| US9561331 | SANOFI AVENTIS US | Drive mechanisms suitable for use in drug delivery devices |
Aug, 2024
(a month from now) | |
| US8512297 | SANOFI AVENTIS US | Pen-type injector |
Sep, 2024
(a month from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Oct 24, 2011 |
Drugs and Companies using INSULIN GLULISINE RECOMBINANT ingredient
Market Authorisation Date: 16 April, 2004
Treatment: NA
Dosage: INJECTABLE
More Information on Dosage
APIDRA SOLOSTAR family patents
17. Armonair Digihaler patent expiration
ARMONAIR DIGIHALER's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9616024 | TEVA PHARM | Process for preparing a medicament |
Sep, 2024
(a month from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jan 27, 2020 |
| New Patient Population(NPP) | Jul 09, 2024 |
| New Strength(NS) | Jul 09, 2024 |
| Pediatric Exclusivity(PED) | Jan 09, 2025 |
Drugs and Companies using FLUTICASONE PROPIONATE ingredient
Market Authorisation Date: 08 April, 2022
Treatment: NA
Dosage: POWDER
More Information on Dosage
ARMONAIR DIGIHALER family patents
18. Armonair Respiclick patent expiration
ARMONAIR RESPICLICK's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9616024 | TEVA PHARM | Process for preparing a medicament |
Sep, 2024
(a month from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jan 27, 2020 |
| New Patient Population(NPP) | Jul 09, 2024 |
| New Strength(NS) | Jul 09, 2024 |
| Pediatric Exclusivity(PED) | Jan 09, 2025 |
Drugs and Companies using FLUTICASONE PROPIONATE ingredient
Market Authorisation Date: 08 April, 2022
Treatment: NA
Dosage: POWDER
More Information on Dosage
ARMONAIR RESPICLICK family patents
19. Auryxia patent expiration
AURYXIA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8338642 | KERYX BIOPHARMS | Ferric organic compounds, uses thereof and methods of making same |
Feb, 2024
(5 months ago) | |
| US7767851 | KERYX BIOPHARMS | Ferric organic compounds, uses thereof and methods of making same |
Feb, 2024
(5 months ago) | |
| US9328133 | KERYX BIOPHARMS | Ferric organic compounds, uses thereof and methods of making same |
Feb, 2024
(5 months ago) | |
| US9757416 | KERYX BIOPHARMS | Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same |
Feb, 2024
(5 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-790) | Nov 06, 2020 |
Drugs and Companies using FERRIC CITRATE ingredient
Market Authorisation Date: 05 September, 2014
Treatment: Control of serum phosphorous levels
Dosage: TABLET
More Information on Dosage
AURYXIA family patents
20. Auvi-q patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8425462 | KALEO INC | Devices, systems, and methods for medicament delivery |
Nov, 2024
(3 months from now) | |
| US9737669 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(3 months from now) | |
| US9833573 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(3 months from now) | |
| US8313466 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(3 months from now) | |
| US10737028 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(3 months from now) | |
| US8361029 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(3 months from now) | |
| US7918823 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(3 months from now) | |
| US8920377 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(3 months from now) | |
| US10314977 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(3 months from now) | |
| US9056170 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(3 months from now) | |
| US8608698 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(3 months from now) | |
Drugs and Companies using EPINEPHRINE ingredient
Market Authorisation Date: 17 November, 2017
Treatment: Method to treat severe allergic emergencies in patients weighing 7.5 to 15 kg (16.5 to 33 lbs)
Dosage: SOLUTION
More Information on Dosage
AUVI-Q family patents
21. Bosulif patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE42376 | PF PRISM CV | Substituted 3-cyanoquinolines |
Apr, 2024
(3 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
USRE42376 (Pediatric) | PF PRISM CV | Substituted 3-cyanoquinolines |
Oct, 2024
(2 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 04, 2017 |
| Orphan Drug Exclusivity(ODE) | Sep 04, 2019 |
| Orphan Drug Exclusivity(ODE-30) | Sep 04, 2019 |
| New Indication(I-759) | Dec 19, 2020 |
| Orphan Drug Exclusivity(ODE-163) | Dec 19, 2024 |
| New Indication(I-923) | Sep 26, 2026 |
| Pediatric Exclusivity(PED) | Mar 26, 2027 |
| Orphan Drug Exclusivity(ODE-444) | Sep 26, 2030 |
Drugs and Companies using BOSUTINIB MONOHYDRATE ingredient
NCE-1 date: 26 March, 2026
Market Authorisation Date: 04 September, 2012
Treatment: NA
Dosage: TABLET; CAPSULE
How can I launch a generic of BOSULIF before it's drug patent expiration?
More Information on Dosage
BOSULIF family patents
22. Brilinta patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE46276 | ASTRAZENECA | Triazolo(4,5-D)pyrimidine compounds |
Oct, 2024
(3 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 20, 2016 |
| New Strength(NS) | Sep 03, 2018 |
| New Indication(I-714) | Sep 03, 2018 |
| New Indication(I-851) | May 28, 2023 |
| New Indication(I-848) | Nov 05, 2023 |
| M(M-283) | May 09, 2025 |
| Pediatric Exclusivity(PED) | Nov 09, 2025 |
Drugs and Companies using TICAGRELOR ingredient
NCE-1 date: 09 November, 2024
Market Authorisation Date: 03 September, 2015
Treatment: Reduction of the rate of a first myocardial infarction or stroke in patients with coronary artery disease at high risk for such events
Dosage: TABLET
How can I launch a generic of BRILINTA before it's drug patent expiration?
More Information on Dosage
BRILINTA family patents
23. Bydureon patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7563871 (Pediatric) | ASTRAZENECA AB | Polymer-based sustained release device |
Oct, 2024
(2 months from now) | |
|
US9238076 (Pediatric) | ASTRAZENECA AB | Polymer-based sustained release device |
Oct, 2024
(2 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jan 27, 2015 |
| M(M-162) | Sep 24, 2018 |
| M(M-212) | Oct 20, 2020 |
| M(M-224) | Apr 02, 2021 |
| M(M-240) | Feb 15, 2022 |
| New Patient Population(NPP) | Jul 22, 2024 |
| Pediatric Exclusivity(PED) | Jan 22, 2025 |
Drugs and Companies using EXENATIDE SYNTHETIC ingredient
Market Authorisation Date: 27 January, 2012
Treatment: NA
Dosage: FOR SUSPENSION, EXTENDED RELEASE
More Information on Dosage
BYDUREON family patents
24. Bydureon Bcise patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7563871 (Pediatric) | ASTRAZENECA AB | Polymer-based sustained release device |
Oct, 2024
(2 months from now) | |
|
US9238076 (Pediatric) | ASTRAZENECA AB | Polymer-based sustained release device |
Oct, 2024
(2 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 20, 2020 |
| M(M-240) | Feb 15, 2022 |
| New Patient Population(NPP) | Jul 22, 2024 |
| Pediatric Exclusivity(PED) | Jan 22, 2025 |
Drugs and Companies using EXENATIDE SYNTHETIC ingredient
Market Authorisation Date: 20 October, 2017
Treatment: NA
Dosage: SUSPENSION, EXTENDED RELEASE
More Information on Dosage
BYDUREON BCISE family patents
25. Bydureon Pen patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US9238076 (Pediatric) | ASTRAZENECA AB | Polymer-based sustained release device |
Oct, 2024
(2 months from now) | |
|
US7563871 (Pediatric) | ASTRAZENECA AB | Polymer-based sustained release device |
Oct, 2024
(2 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jan 27, 2015 |
| M(M-162) | Sep 24, 2018 |
| M(M-212) | Oct 20, 2020 |
| M(M-224) | Apr 02, 2021 |
| M(M-240) | Feb 15, 2022 |
| New Patient Population(NPP) | Jul 22, 2024 |
| Pediatric Exclusivity(PED) | Jan 22, 2025 |
Drugs and Companies using EXENATIDE SYNTHETIC ingredient
Market Authorisation Date: 27 January, 2012
Treatment: NA
Dosage: FOR SUSPENSION, EXTENDED RELEASE
More Information on Dosage
BYDUREON PEN family patents
26. Cabometyx patent expiration
Can you believe CABOMETYX received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8497284 | EXELIXIS INC | C-met modulators and method of use |
Sep, 2024
(2 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 29, 2017 |
| New Product(NP) | Apr 25, 2019 |
| New Indication(I-760) | Dec 19, 2020 |
| New Indication(I-792) | Jan 14, 2022 |
| New Indication(I-854) | Jan 22, 2024 |
| New Indication(I-873) | Sep 17, 2024 |
| Orphan Drug Exclusivity(ODE-227) | Jan 14, 2026 |
| Orphan Drug Exclusivity(ODE-375) | Sep 17, 2028 |
Drugs and Companies using CABOZANTINIB S-MALATE ingredient
NCE-1 date: 29 November, 2016
Market Authorisation Date: 25 April, 2016
Treatment: Treatment of advanced renal cell carcinoma
Dosage: TABLET
How can I launch a generic of CABOMETYX before it's drug patent expiration?
More Information on Dosage
CABOMETYX family patents
27. Combivent Respimat patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7284474 | BOEHRINGER INGELHEIM | Piston-pumping system having o-ring seal properties |
Aug, 2024
(a month from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 07, 2014 |
Drugs and Companies using ALBUTEROL SULFATE; IPRATROPIUM BROMIDE ingredient
Market Authorisation Date: 07 October, 2011
Treatment: NA
Dosage: SPRAY, METERED
How can I launch a generic of COMBIVENT RESPIMAT before it's drug patent expiration?
More Information on Dosage
COMBIVENT RESPIMAT family patents
28. Defencath patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8541393 | CORMEDIX | Antimicrobial locking solutions comprising taurinamide derivatives and biologically acceptable salts and acids, with the addition of small concentrations of heparin |
Nov, 2024
(3 months from now) | |
| US9339036 | CORMEDIX | Antimicrobial locking solutions comprising taurinamide derivatives and biologically acceptable salts and acids, with the addition of small concentrations of heparin |
Nov, 2024
(3 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 15, 2028 |
| Generating Antibiotic Incentives Now(GAIN) | Nov 15, 2033 |
Drugs and Companies using HEPARIN SODIUM; TAUROLIDINE ingredient
NCE-1 date: 15 November, 2032
Market Authorisation Date: 15 November, 2023
Treatment: A catheter lock solution to reduce catheter-related bloodstream infections in adult patients receiving hemodialysis through a central venous catheter
Dosage: SOLUTION
More Information on Dosage
DEFENCATH family patents
29. Dextenza patent expiration
DEXTENZA IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9254267 | OCULAR THERAPEUTIX | Composite hydrogel drug delivery systems |
Sep, 2024
(a month from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Nov 30, 2021 |
| New Indication(I-800) | Jun 20, 2022 |
| New Indication(I-876) | Oct 07, 2024 |
Drugs and Companies using DEXAMETHASONE ingredient
Market Authorisation Date: 30 November, 2018
Treatment: NA
Dosage: INSERT
More Information on Dosage
DEXTENZA family patents
30. Differin patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7737181 | GALDERMA LABS LP | Pharmaceutical compositions comprising 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders |
Aug, 2024
(a month from now) | |
Drugs and Companies using ADAPALENE ingredient
Market Authorisation Date: 19 June, 2007
Treatment: NA
Dosage: GEL
How can I launch a generic of DIFFERIN before it's drug patent expiration?
More Information on Dosage
DIFFERIN family patents
31. Diprivan patent expiration
DIPRIVAN IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8476010 | FRESENIUS KABI USA | Propofol formulations with non-reactive container closures |
Dec, 2024
(4 months from now) | |
Drugs and Companies using PROPOFOL ingredient
Market Authorisation Date: 02 October, 1989
Treatment: NA
Dosage: INJECTABLE
How can I launch a generic of DIPRIVAN before it's drug patent expiration?
More Information on Dosage
DIPRIVAN family patents
32. Elelyso patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8741620 | PFIZER | Human lysosomal proteins from plant cell culture |
Feb, 2024
(4 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 01, 2017 |
| New Patient Population(NPP) | Aug 27, 2017 |
Drugs and Companies using TALIGLUCERASE ALFA ingredient
NCE-1 date: 01 May, 2016
Market Authorisation Date: 01 May, 2012
Treatment: NA
Dosage: POWDER
More Information on Dosage
ELELYSO family patents
33. Envarsus Xr patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8623410 | VELOXIS PHARMS INC | Modified release compositions comprising tacrolimus |
Aug, 2024
(a month from now) | |
| US7994214 | VELOXIS PHARMS INC | Solid dispersions comprising tacrolimus |
Aug, 2024
(a month from now) | |
| US9763920 | VELOXIS PHARMS INC | Solid dispersions comprising tacrolimus |
Aug, 2024
(a month from now) | |
| US11077096 | VELOXIS PHARMS INC | Modified release compositions comprising tacrolimus |
Aug, 2024
(a month from now) | |
| US9161907 | VELOXIS PHARMS INC | Modified release compositions comprising tacrolimus |
Aug, 2024
(a month from now) | |
| US8486993 | VELOXIS PHARMS INC | Solid dispersions comprising tacrolimus |
Aug, 2024
(a month from now) | |
| US8889185 | VELOXIS PHARMS INC | Modified release compositions comprising tacrolimus |
Aug, 2024
(a month from now) | |
| US9757362 | VELOXIS PHARMS INC | Modified release compositions comprising tacrolimus |
Aug, 2024
(a month from now) | |
| US8617599 | VELOXIS PHARMS INC | Modified release compositions comprising tacrolimus |
Aug, 2024
(a month from now) | |
| US10548880 | VELOXIS PHARMS INC | Solid dispersions comprising tacrolimus |
Aug, 2024
(a month from now) | |
| US8591946 | VELOXIS PHARMS INC | Modified release compositions comprising tacrolimus |
Aug, 2024
(a month from now) | |
| US8623411 | VELOXIS PHARMS INC | Modified release compositions comprising tacrolimus |
Aug, 2024
(a month from now) | |
| US8889186 | VELOXIS PHARMS INC | Modified release compositions comprising tacrolimus |
Aug, 2024
(a month from now) | |
| US8586084 | VELOXIS PHARMS INC | Modified release compositions comprising tacrolimus |
Aug, 2024
(a month from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Jul 10, 2022 |
| Orphan Drug Exclusivity(ODE-94) | Jul 10, 2022 |
Drugs and Companies using TACROLIMUS ingredient
Market Authorisation Date: 10 July, 2015
Treatment: Prophylaxis of organ rejection; Prophylaxis of organ rejection in de novo transplant patient
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of ENVARSUS XR before it's drug patent expiration?
More Information on Dosage
ENVARSUS XR family patents
34. Epiduo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7964202 | GALDERMA LABS LP | Method for treatment of common acne |
Sep, 2024
(a month from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Dec 08, 2011 |
| New Patient Population(NPP) | Feb 01, 2016 |
Drugs and Companies using ADAPALENE; BENZOYL PEROXIDE ingredient
Market Authorisation Date: 08 December, 2008
Treatment: Treatment of acne
Dosage: GEL
How can I launch a generic of EPIDUO before it's drug patent expiration?
More Information on Dosage
EPIDUO family patents
35. Evzio patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9737669 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(3 months from now) | |
| US8313466 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(3 months from now) | |
| US8608698 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(3 months from now) | |
| US9056170 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(3 months from now) | |
| US10314977 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(3 months from now) | |
| US7918823 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(3 months from now) | |
| US10737028 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(3 months from now) | |
| US8425462 | KALEO INC | Devices, systems, and methods for medicament delivery |
Nov, 2024
(3 months from now) | |
| US8361029 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(3 months from now) | |
Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 03 April, 2014
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
EVZIO family patents
36. Evzio (autoinjector) patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8608698 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(3 months from now) | |
| US8361029 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(3 months from now) | |
| US8425462 | KALEO INC | Devices, systems, and methods for medicament delivery |
Nov, 2024
(3 months from now) | |
| US8313466 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(3 months from now) | |
| US7918823 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(3 months from now) | |
| US9056170 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(3 months from now) | |
| US10737028 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(3 months from now) | |
| US9737669 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(3 months from now) | |
| US10314977 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(3 months from now) | |
Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 19 October, 2016
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
EVZIO (AUTOINJECTOR) family patents
37. Fenoglide patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9173847 | SALIX | Tablet comprising a fibrate |
Oct, 2024
(2 months from now) | |
| US8124125 | SALIX | Solid dosage form comprising a fibrate |
Oct, 2024
(2 months from now) | |
| US8481078 | SALIX | Solid dosage form comprising a fibrate |
Oct, 2024
(2 months from now) | |
| US7658944 | SALIX | Solid dosage form comprising a fibrate |
Dec, 2024
(4 months from now) | |
Drugs and Companies using FENOFIBRATE ingredient
Market Authorisation Date: 10 August, 2007
Treatment: For reducing total cholesterol (total-c), ldl-c, apo-lipoprotein b, or total triglycerides, and treating hypertriglyceridemia; Use of fenofibrate for reducing elevated total cholesterol (total-c), ldl...
Dosage: TABLET
How can I launch a generic of FENOGLIDE before it's drug patent expiration?
More Information on Dosage
FENOGLIDE family patents
38. Fentora patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8092832 | CEPHALON | Generally linear effervescent oral fentanyl dosage form and methods of administering |
Dec, 2024
(5 months from now) | |
| US8119158 | CEPHALON | Effervescent oral fentanyl dosage form and methods of administering fentanyl |
Dec, 2024
(5 months from now) | |
Drugs and Companies using FENTANYL CITRATE ingredient
Market Authorisation Date: 25 September, 2006
Treatment: NA
Dosage: TABLET
How can I launch a generic of FENTORA before it's drug patent expiration?
More Information on Dosage
FENTORA family patents
39. Flonase Sensimist Allergy Relief patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9320862 | HALEON US HOLDINGS | Fluid dispensing device |
Nov, 2024
(3 months from now) | |
Drugs and Companies using FLUTICASONE FUROATE ingredient
Market Authorisation Date: 02 August, 2016
Treatment: NA
Dosage: SPRAY, METERED
More Information on Dosage
FLONASE SENSIMIST ALLERGY RELIEF family patents
40. Fosrenol patent expiration
FOSRENOL's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7381428 | TAKEDA PHARMS USA | Stabilized lanthanum carbonate compositions |
Aug, 2024
(a month from now) | |
| US7465465 | TAKEDA PHARMS USA | Pharmaceutical formulation comprising lanthanum compounds |
Aug, 2024
(a month from now) | |
Drugs and Companies using LANTHANUM CARBONATE ingredient
Market Authorisation Date: 23 November, 2005
Treatment: Reduction of serum phosphate in patients with end stage renal disease
Dosage: POWDER; TABLET, CHEWABLE
How can I launch a generic of FOSRENOL before it's drug patent expiration?
More Information on Dosage
FOSRENOL family patents
41. Fotivda patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7166722 | AVEO PHARMS | N-{2-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-n′-(5-methyl-3-isoxazolyl)urea salt in crystalline form |
Nov, 2024
(3 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 10, 2026 |
Drugs and Companies using TIVOZANIB HYDROCHLORIDE ingredient
NCE-1 date: 10 March, 2025
Market Authorisation Date: 10 March, 2021
Treatment: NA
Dosage: CAPSULE
More Information on Dosage
FOTIVDA family patents
42. Givlaari patent expiration
Can you believe GIVLAARI received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9708610 | ALNYLAM PHARMS INC | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation |
Jan, 2024
(6 months ago) | |
| US10273477 | ALNYLAM PHARMS INC | Therapeutic compositions |
Mar, 2024
(4 months ago) | |
| US9708615 | ALNYLAM PHARMS INC | Therapeutic compositions |
Mar, 2024
(4 months ago) | |
| US11530408 | ALNYLAM PHARMS INC | Therapeutic compositions |
May, 2024
(2 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 20, 2024 |
| Orphan Drug Exclusivity(ODE-273) | Nov 20, 2026 |
Drugs and Companies using GIVOSIRAN SODIUM ingredient
NCE-1 date: 21 November, 2023
Market Authorisation Date: 20 November, 2019
Treatment: Treatment of acute hepatic porphyria
Dosage: SOLUTION
More Information on Dosage
GIVLAARI family patents
43. Humalog Kwikpen patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7291132 | ELI LILLY AND CO | Medication dispensing apparatus with triple screw threads for mechanical advantage |
Aug, 2024
(15 days from now) | |
Drugs and Companies using INSULIN LISPRO RECOMBINANT ingredient
Market Authorisation Date: 26 May, 2015
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
HUMALOG KWIKPEN family patents
44. Humalog Kwikpen patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7291132 | LILLY | Medication dispensing apparatus with triple screw threads for mechanical advantage |
Aug, 2024
(15 days from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| NR(NR) | Oct 12, 2015 |
Drugs and Companies using INSULIN LISPRO RECOMBINANT ingredient
Market Authorisation Date: 15 November, 2019
Treatment: NA
Dosage: INJECTABLE
More Information on Dosage
HUMALOG KWIKPEN family patents
45. Humalog Mix 50/50 Kwikpen patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7291132 | LILLY | Medication dispensing apparatus with triple screw threads for mechanical advantage |
Aug, 2024
(15 days from now) | |
Market Authorisation Date: 22 December, 1999
Treatment: NA
Dosage: INJECTABLE
More Information on Dosage
HUMALOG MIX 50/50 KWIKPEN family patents
46. Humalog Mix 75/25 Kwikpen patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7291132 | LILLY | Medication dispensing apparatus with triple screw threads for mechanical advantage |
Aug, 2024
(15 days from now) | |
Market Authorisation Date: 22 December, 1999
Treatment: NA
Dosage: INJECTABLE
More Information on Dosage
HUMALOG MIX 75/25 KWIKPEN family patents
47. Humulin 70/30 patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7291132 | LILLY | Medication dispensing apparatus with triple screw threads for mechanical advantage |
Aug, 2024
(15 days from now) | |
Market Authorisation Date: 25 April, 1989
Treatment: NA
Dosage: INJECTABLE
More Information on Dosage
HUMULIN 70/30 family patents
48. Humulin 70/30 Pen patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7291132 | LILLY | Medication dispensing apparatus with triple screw threads for mechanical advantage |
Aug, 2024
(15 days from now) | |
Market Authorisation Date: 25 April, 1989
Treatment: NA
Dosage: INJECTABLE
More Information on Dosage
HUMULIN 70/30 PEN family patents
49. Humulin N patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7291132 | LILLY | Medication dispensing apparatus with triple screw threads for mechanical advantage |
Aug, 2024
(15 days from now) | |
Drugs and Companies using INSULIN SUSP ISOPHANE RECOMBINANT HUMAN ingredient
Market Authorisation Date: 28 October, 1982
Treatment: NA
Dosage: INJECTABLE
More Information on Dosage
HUMULIN N family patents
50. Humulin R patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7291132 | LILLY | Medication dispensing apparatus with triple screw threads for mechanical advantage |
Aug, 2024
(15 days from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| NR(NR) | Mar 25, 2014 |
Drugs and Companies using INSULIN RECOMBINANT HUMAN ingredient
Market Authorisation Date: 29 December, 2015
Treatment: NA
Dosage: INJECTABLE
More Information on Dosage
HUMULIN R family patents
51. Hycamtin patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8158645 | SANDOZ | Compound, corresponding compositions, preparation and/or treatment methods |
Dec, 2024
(4 months from now) | |
Drugs and Companies using TOPOTECAN HYDROCHLORIDE ingredient
Market Authorisation Date: 11 October, 2007
Treatment: NA
Dosage: CAPSULE
More Information on Dosage
HYCAMTIN family patents
52. Invokamet patent expiration
INVOKAMET's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8785403 | JANSSEN PHARMS | Glucopyranoside compound |
Jul, 2024
(5 days from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Aug 08, 2017 |
| New Chemical Entity Exclusivity(NCE) | Mar 29, 2018 |
| New Indication(I-735) | May 20, 2019 |
| M(M-197) | Feb 01, 2020 |
| New Indication(I-788) | Oct 29, 2021 |
Drugs and Companies using CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient
NCE-1 date: 29 March, 2017
Market Authorisation Date: 08 August, 2014
Treatment: NA
Dosage: TABLET
How can I launch a generic of INVOKAMET before it's drug patent expiration?
More Information on Dosage
INVOKAMET family patents
53. Invokamet Xr patent expiration
INVOKAMET XR's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8785403 | JANSSEN PHARMS | Glucopyranoside compound |
Jul, 2024
(5 days from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Aug 08, 2017 |
| New Chemical Entity Exclusivity(NCE) | Mar 29, 2018 |
| New Indication(I-735) | May 20, 2019 |
| New Indication(I-788) | Oct 29, 2021 |
Drugs and Companies using CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient
NCE-1 date: 29 March, 2017
Market Authorisation Date: 20 September, 2016
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of INVOKAMET XR before it's drug patent expiration?
More Information on Dosage
INVOKAMET XR family patents
54. Iqirvo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7943661 | IPSEN | Substituted 1,3-diphenylprop-2-en-1-one derivatives and preparation and uses thereof |
Sep, 2024
(a month from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7632870 | IPSEN | Composition based on substituted 1,3-diphenylprop-2-en-1-one derivatives, preparation and uses thereof |
Sep, 2024
(a month from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 10, 2029 |
Drugs and Companies using ELAFIBRANOR ingredient
NCE-1 date: 10 June, 2028
Market Authorisation Date: 10 June, 2024
Treatment: NA
Dosage: TABLET
More Information on Dosage
IQIRVO family patents
55. Ixempra Kit patent expiration
IXEMPRA KIT IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7312237 | R-PHARM US LLC | Combination of epothilone analogs and chemotherapeutic agents for the treatment of prolilferative diseases |
Aug, 2024
(27 days from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 16, 2012 |
| Pediatric Exclusivity(PED) | Apr 18, 2015 |
| M(M-61) | Oct 18, 2014 |
Drugs and Companies using IXABEPILONE ingredient
NCE-1 date: 18 April, 2014
Market Authorisation Date: 16 October, 2007
Treatment: Use of ixabepilone in combination with capecitabine in treatment of metastasis breast cancer
Dosage: INJECTABLE
How can I launch a generic of IXEMPRA KIT before it's drug patent expiration?
More Information on Dosage
IXEMPRA KIT family patents
56. Kaletra patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8399015 | ABBVIE | Solid pharmaceutical dosage form |
Aug, 2024
(a month from now) | |
| US8268349 | ABBVIE | Solid pharmaceutical dosage form |
Aug, 2024
(a month from now) | |
| US8691878 | ABBVIE | Solid pharmaceutical dosage form |
Aug, 2024
(a month from now) | |
| US8309613 | ABBVIE | Solid pharmaceutical dosage form |
Dec, 2024
(4 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-124) | Apr 27, 2013 |
Drugs and Companies using LOPINAVIR; RITONAVIR ingredient
Market Authorisation Date: 09 November, 2007
Treatment: Treatment of hiv-1 infection in combination with other antiretroviral agents; Treatment of hiv-infection in combination with other antiretroviral agents
Dosage: TABLET
How can I launch a generic of KALETRA before it's drug patent expiration?
More Information on Dosage
KALETRA family patents
57. Kuvan patent expiration
KUVAN's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7947681 | BIOMARIN PHARM | Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring |
Nov, 2024
(3 months from now) | |
| US8067416 | BIOMARIN PHARM | Methods and compositions for the treatment of metabolic disorders |
Nov, 2024
(3 months from now) | |
| US7612073 | BIOMARIN PHARM | Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring |
Nov, 2024
(3 months from now) | |
| US9433624 | BIOMARIN PHARM | Methods and compositions for the treatment of metabolic disorders |
Nov, 2024
(3 months from now) | |
| US7727987 | BIOMARIN PHARM | Crystalline forms of (6R)-L-erythro-tetrahydrobiopterin dihydrochloride |
Nov, 2024
(3 months from now) | |
| US7566714 | BIOMARIN PHARM | Methods and compositions for the treatment of metabolic disorders |
Nov, 2024
(3 months from now) | |
| US8318745 | BIOMARIN PHARM | Crystalline forms of (6R)-L-erythro-tetrahydrobiopterin dihydrochloride |
Nov, 2024
(3 months from now) | |
| USRE43797 | BIOMARIN PHARM | Methods of administering tetrahydrobiopterin |
Nov, 2024
(3 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 13, 2012 |
| Orphan Drug Exclusivity(ODE) | Dec 13, 2014 |
| New Patient Population(NPP) | Apr 23, 2017 |
| Pediatric Exclusivity(PED) | Oct 23, 2017 |
Drugs and Companies using SAPROPTERIN DIHYDROCHLORIDE ingredient
NCE-1 date: 23 October, 2016
Market Authorisation Date: 13 December, 2007
Treatment: To reduce blood phenylalanine (phe) levels in patients with hyperphenylalaninemia (hpa); Method of use for reducing blood phenylalanine levels in a human suffering from hyperphenylalaninemia; To reduc...
Dosage: TABLET; POWDER
How can I launch a generic of KUVAN before it's drug patent expiration?
More Information on Dosage
KUVAN family patents
58. Lantus Solostar patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9604009 | SANOFI AVENTIS US | Drive mechanisms suitable for use in drug delivery devices |
Aug, 2024
(22 days from now) | |
| US9533105 | SANOFI AVENTIS US | Drive mechanisms suitable for use in drug delivery devices |
Aug, 2024
(23 days from now) | |
| US9623189 | SANOFI AVENTIS US | Relating to drive mechanisms suitable for use in drug delivery devices |
Aug, 2024
(25 days from now) | |
| US9561331 | SANOFI AVENTIS US | Drive mechanisms suitable for use in drug delivery devices |
Aug, 2024
(a month from now) | |
| US8512297 | SANOFI AVENTIS US | Pen-type injector |
Sep, 2024
(a month from now) | |
Drugs and Companies using INSULIN GLARGINE RECOMBINANT ingredient
Market Authorisation Date: 27 April, 2007
Treatment: NA
Dosage: INJECTABLE
More Information on Dosage
LANTUS SOLOSTAR family patents
59. Latuda patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US9174975 (Pediatric) | SUNOVION PHARMS INC | Remedy for integration dysfunction syndrome |
Aug, 2024
(26 days from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-134) | Apr 26, 2015 |
| New Chemical Entity Exclusivity(NCE) | Oct 28, 2015 |
| New Indication(I-674) | Jun 28, 2016 |
| M(M-195) | Jan 27, 2020 |
| Pediatric Exclusivity(PED) | Jul 27, 2020 |
| New Patient Population(NPP) | Mar 05, 2021 |
Drugs and Companies using LURASIDONE HYDROCHLORIDE ingredient
NCE-1 date: 28 July, 2019
Market Authorisation Date: 07 December, 2011
Treatment: NA
Dosage: TABLET
How can I launch a generic of LATUDA before it's drug patent expiration?
More Information on Dosage
LATUDA family patents
60. Lazanda patent expiration
LAZANDA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8216604 | BTCP PHARMA | Method of managing or treating pain |
Oct, 2024
(2 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Jun 30, 2014 |
Drugs and Companies using FENTANYL CITRATE ingredient
Market Authorisation Date: 30 June, 2011
Treatment: Management of breakthrough pain in patients with cancer
Dosage: SPRAY, METERED
More Information on Dosage
LAZANDA family patents
61. Leqvio patent expiration
Can you believe LEQVIO received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9708610 | NOVARTIS | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation |
Jan, 2024
(6 months ago) | |
| US9708615 | NOVARTIS | Therapeutic compositions |
Mar, 2024
(4 months ago) | |
| US10273477 | NOVARTIS | Therapeutic compositions |
Mar, 2024
(4 months ago) | |
| US10669544 | NOVARTIS | Therapeutic compositions |
Mar, 2024
(4 months ago) | |
| US11530408 | NOVARTIS | Therapeutic compositions |
May, 2024
(2 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 22, 2026 |
Drugs and Companies using INCLISIRAN SODIUM ingredient
NCE-1 date: 22 December, 2025
Market Authorisation Date: 22 December, 2021
Treatment: As an adjunct to diet and statin therapy for the treatment of adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (hefh), by inhibiting expression of the pcsk9 gen...
Dosage: SOLUTION
More Information on Dosage
LEQVIO family patents
62. Linzess patent expiration
LINZESS's oppositions filed in EPO
Can you believe LINZESS received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7745409 | ABBVIE | Methods and compositions for the treatment of gastrointestinal disorders |
Jan, 2024
(5 months ago) | |
| US8080526 | ABBVIE | Methods and compositions for the treatment of gastrointestinal disorders |
Jan, 2024
(5 months ago) | |
| US7704947 | ABBVIE | Methods and compositions for the treatment of gastrointestinal disorders |
Jan, 2024
(5 months ago) | |
| US7371727 | ABBVIE | Methods and compositions for the treatment of gastrointestinal disorders |
Jan, 2024
(5 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 30, 2017 |
| New Strength(NS) | Jan 25, 2020 |
| New Indication(I-921) | Jun 12, 2026 |
Drugs and Companies using LINACLOTIDE ingredient
NCE-1 date: 30 August, 2016
Market Authorisation Date: 25 January, 2017
Treatment: NA
Dosage: CAPSULE
How can I launch a generic of LINZESS before it's drug patent expiration?
More Information on Dosage
LINZESS family patents
63. Livalo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8557993 (Pediatric) | KOWA CO | Crystalline forms of pitavastatin calcium |
Aug, 2024
(8 days from now) | |
|
US7022713 (Pediatric) | KOWA CO | Hyperlipemia therapeutic agent |
Aug, 2024
(25 days from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 03, 2014 |
| New Patient Population(NPP) | May 16, 2022 |
| Pediatric Exclusivity(PED) | Nov 16, 2022 |
Drugs and Companies using PITAVASTATIN CALCIUM ingredient
NCE-1 date: 16 November, 2021
Market Authorisation Date: 03 August, 2009
Treatment: NA
Dosage: TABLET
How can I launch a generic of LIVALO before it's drug patent expiration?
More Information on Dosage
LIVALO family patents
64. Lonhala Magnair Kit patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7458372 | SUMITOMO PHARMA AM | Inhalation therapy device |
Nov, 2024
(3 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 05, 2020 |
Drugs and Companies using GLYCOPYRROLATE ingredient
Market Authorisation Date: 05 December, 2017
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
LONHALA MAGNAIR KIT family patents
65. Lupkynis patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7332472 | AURINIA | Cyclosporine analogue mixtures and their use as immunomodulating agents |
Oct, 2024
(2 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 22, 2026 |
Drugs and Companies using VOCLOSPORIN ingredient
NCE-1 date: 22 January, 2025
Market Authorisation Date: 22 January, 2021
Treatment: Treatment of patients with active lupus nephritis
Dosage: CAPSULE
More Information on Dosage
LUPKYNIS family patents
66. Lynparza patent expiration
LYNPARZA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7981889 | ASTRAZENECA | Phthalazinone derivatives |
Oct, 2024
(2 months from now) | |
| US7449464 | ASTRAZENECA | Phthalazinone derivatives |
Oct, 2024
(2 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 19, 2019 |
| Orphan Drug Exclusivity(ODE-83) | Dec 19, 2021 |
| Orphan Drug Exclusivity(ODE) | Dec 19, 2021 |
Drugs and Companies using OLAPARIB ingredient
NCE-1 date: 19 December, 2018
Market Authorisation Date: 19 December, 2014
Treatment: NA
Dosage: CAPSULE; TABLET
How can I launch a generic of LYNPARZA before it's drug patent expiration?
More Information on Dosage
LYNPARZA family patents
67. Methylin patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7691880 | SPECGX LLC | Methylphenidate solution and associated methods of administration and production |
Oct, 2024
(2 months from now) | |
Drugs and Companies using METHYLPHENIDATE HYDROCHLORIDE ingredient
Market Authorisation Date: 19 December, 2002
Treatment: NA
Dosage: SOLUTION
How can I launch a generic of METHYLIN before it's drug patent expiration?
More Information on Dosage
METHYLIN family patents
68. Movantik patent expiration
MOVANTIK's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8067431 | VALINOR | Chemically modified small molecules |
Dec, 2024
(4 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 16, 2019 |
Drugs and Companies using NALOXEGOL OXALATE ingredient
NCE-1 date: 16 September, 2018
Market Authorisation Date: 16 September, 2014
Treatment: Treatment of opioid-induced constipation
Dosage: TABLET
How can I launch a generic of MOVANTIK before it's drug patent expiration?
More Information on Dosage
MOVANTIK family patents
69. Moviprep patent expiration
MOVIPREP's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7169381 | SALIX PHARMS | Colon cleansing compositions and methods |
Sep, 2024
(a month from now) | |
| US7658914 | SALIX PHARMS | Colon cleansing compositions |
Sep, 2024
(a month from now) | |
Market Authorisation Date: 02 August, 2006
Treatment: NA
Dosage: FOR SOLUTION
How can I launch a generic of MOVIPREP before it's drug patent expiration?
More Information on Dosage
MOVIPREP family patents
70. Mulpleta patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7601746 | VANCOCIN ITALIA | Compounds exhibiting thrombopoietin receptor agonism |
Sep, 2024
(a month from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 31, 2023 |
Drugs and Companies using LUSUTROMBOPAG ingredient
NCE-1 date: 31 July, 2022
Market Authorisation Date: 31 July, 2018
Treatment: Treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure
Dosage: TABLET
More Information on Dosage
MULPLETA family patents
71. Naloxone Hydrochloride (autoinjector) patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8425462 | KALEO INC | Devices, systems, and methods for medicament delivery |
Nov, 2024
(3 months from now) | |
| US8361029 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(3 months from now) | |
| US9737669 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(3 months from now) | |
| US9056170 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(3 months from now) | |
| US10314977 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(3 months from now) | |
| US7918823 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(3 months from now) | |
| US10737028 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(3 months from now) | |
| US8313466 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(3 months from now) | |
| US8608698 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(3 months from now) | |
Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 28 February, 2022
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
NALOXONE HYDROCHLORIDE (AUTOINJECTOR) family patents
72. Nascobal patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9415007 | ENDO OPERATIONS | Cyanocobalamin low viscosity aqueous formulations for intranasal delivery |
Jul, 2024
(3 days from now) | |
| US7229636 | ENDO OPERATIONS | Cyanocobalamin low viscosity aqueous formulations for intranasal delivery |
Aug, 2024
(7 days from now) | |
| US8003353 | ENDO OPERATIONS | Cyanocobalamin low viscosity aqueous formulations for intranasal delivery |
Aug, 2024
(7 days from now) | |
| US7879349 | ENDO OPERATIONS | Cyanocobalamin low viscosity aqueous formulations for intranasal delivery |
Aug, 2024
(7 days from now) | |
Drugs and Companies using CYANOCOBALAMIN ingredient
Market Authorisation Date: 31 January, 2005
Treatment: Supplement for vitamin b12 deficiencies; Nasal administration of cyanocobalamin; Cyanocobalamin administration through nasal infusion
Dosage: SPRAY, METERED
How can I launch a generic of NASCOBAL before it's drug patent expiration?
More Information on Dosage
NASCOBAL family patents
73. Ninlaro patent expiration
NINLARO's oppositions filed in EPO
Can you believe NINLARO received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8546608 | TAKEDA PHARMS USA | Proteasome inhibitors and methods of using the same |
Aug, 2024
(18 days from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9233115 | TAKEDA PHARMS USA | Proteasome inhibitors and methods of using the same |
Aug, 2024
(18 days from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 20, 2020 |
| Orphan Drug Exclusivity(ODE) | Nov 20, 2022 |
| Orphan Drug Exclusivity(ODE-103) | Nov 20, 2022 |
Drugs and Companies using IXAZOMIB CITRATE ingredient
NCE-1 date: 21 November, 2019
Market Authorisation Date: 20 November, 2015
Treatment: Use in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy
Dosage: CAPSULE
How can I launch a generic of NINLARO before it's drug patent expiration?
More Information on Dosage
NINLARO family patents
74. Noctiva patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7799761 | ACERUS PHARMS | Pharmaceutical compositions including low dosages of desmopressin |
Sep, 2024
(2 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 03, 2020 |
Drugs and Companies using DESMOPRESSIN ACETATE ingredient
Market Authorisation Date: 03 March, 2017
Treatment: NA
Dosage: SPRAY, METERED
More Information on Dosage
NOCTIVA family patents
75. Norvir patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8399015 | ABBVIE | Solid pharmaceutical dosage form |
Aug, 2024
(a month from now) | |
| US8268349 | ABBVIE | Solid pharmaceutical dosage form |
Aug, 2024
(a month from now) | |
| US8691878 | ABBVIE | Solid pharmaceutical dosage form |
Aug, 2024
(a month from now) | |
Drugs and Companies using RITONAVIR ingredient
Market Authorisation Date: 10 February, 2010
Treatment: Treatment of hiv-infection in combination with other antiretroviral agents
Dosage: TABLET
How can I launch a generic of NORVIR before it's drug patent expiration?
More Information on Dosage
NORVIR family patents
76. Nourianz patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7541363 | KYOWA KIRIN | Microcrystal |
Nov, 2024
(3 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 27, 2024 |
Drugs and Companies using ISTRADEFYLLINE ingredient
NCE-1 date: 28 August, 2023
Market Authorisation Date: 27 August, 2019
Treatment: NA
Dosage: TABLET
More Information on Dosage
NOURIANZ family patents
77. Nucynta Er patent expiration
NUCYNTA ER's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8114383 | COLLEGIUM PHARM INC | Abuse-proofed dosage form |
Oct, 2024
(2 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 20, 2013 |
| New Dosage Form(NDF) | Aug 25, 2014 |
| New Indication(I-656) | Aug 28, 2015 |
Drugs and Companies using TAPENTADOL HYDROCHLORIDE ingredient
NCE-1 date: 20 November, 2012
Market Authorisation Date: 25 August, 2011
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of NUCYNTA ER before it's drug patent expiration?
More Information on Dosage
NUCYNTA ER family patents
78. Ofev patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7119093 | BOEHRINGER INGELHEIM | 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate and the use thereof as a pharmaceutical composition |
Feb, 2024
(5 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 15, 2019 |
| Orphan Drug Exclusivity(ODE-77) | Oct 15, 2021 |
| Orphan Drug Exclusivity(ODE) | Oct 15, 2021 |
| New Indication(I-805) | Sep 06, 2022 |
| New Indication(I-825) | Mar 09, 2023 |
| Orphan Drug Exclusivity(ODE-261) | Sep 06, 2026 |
| Pediatric Exclusivity(PED) | Mar 06, 2027 |
Drugs and Companies using NINTEDANIB ESYLATE ingredient
NCE-1 date: 06 March, 2026
Market Authorisation Date: 15 October, 2014
Treatment: NA
Dosage: CAPSULE
How can I launch a generic of OFEV before it's drug patent expiration?
More Information on Dosage
OFEV family patents
79. Omegaven patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10350186 | FRESENIUS KABI USA | Treatment and prevention of liver disease associated with parenteral nutrition (PN) |
Nov, 2024
(3 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 27, 2023 |
| Orphan Drug Exclusivity(ODE-202) | Jul 27, 2025 |
Drugs and Companies using FISH OIL TRIGLYCERIDES ingredient
NCE-1 date: 27 July, 2022
Market Authorisation Date: 27 July, 2018
Treatment: Treatment of parenteral nutrition-associated cholestasis in patients under the age of 12
Dosage: EMULSION
More Information on Dosage
OMEGAVEN family patents
80. Omontys patent expiration
Can you believe OMONTYS received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7084245 | TAKEDA PHARMS USA | Peptides that bind to the erythropoietin receptor |
May, 2024
(2 months ago) | |
| US7414105 | TAKEDA PHARMS USA | Peptides that bind to the erythropoietin receptor |
May, 2024
(2 months ago) | |
| US7919118 | TAKEDA PHARMS USA | Spacer moiety for poly (ethylene glycol) modified peptide based compounds |
May, 2024
(2 months ago) | |
| US7528104 | TAKEDA PHARMS USA | Peptides that bind to the erythropoietin receptor |
May, 2024
(2 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 27, 2017 |
Drugs and Companies using PEGINESATIDE ACETATE ingredient
NCE-1 date: 27 March, 2016
Market Authorisation Date: 27 March, 2012
Treatment: Treatment of anemia due to chronic kidney disease
Dosage: SOLUTION
More Information on Dosage
OMONTYS family patents
81. Omontys Preservative Free patent expiration
Can you believe OMONTYS PRESERVATIVE FREE received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7528104 | TAKEDA PHARMS USA | Peptides that bind to the erythropoietin receptor |
May, 2024
(2 months ago) | |
| US7414105 | TAKEDA PHARMS USA | Peptides that bind to the erythropoietin receptor |
May, 2024
(2 months ago) | |
| US7084245 | TAKEDA PHARMS USA | Peptides that bind to the erythropoietin receptor |
May, 2024
(2 months ago) | |
| US7919118 | TAKEDA PHARMS USA | Spacer moiety for poly (ethylene glycol) modified peptide based compounds |
May, 2024
(2 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 27, 2017 |
Drugs and Companies using PEGINESATIDE ACETATE ingredient
NCE-1 date: 27 March, 2016
Market Authorisation Date: 27 March, 2012
Treatment: Treatment of anemia due to chronic kidney disease
Dosage: SOLUTION
More Information on Dosage
OMONTYS PRESERVATIVE FREE family patents
82. Opana Er patent expiration
OPANA ER's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8114383 | ENDO PHARMS | Abuse-proofed dosage form |
Aug, 2024
(14 days from now) | |
Drugs and Companies using OXYMORPHONE HYDROCHLORIDE ingredient
Market Authorisation Date: 09 December, 2011
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE
More Information on Dosage
OPANA ER family patents
83. Orenitram patent expiration
ORENITRAM's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9050311 | UNITED THERAP | Compounds and methods for delivery of prostacyclin analogs |
May, 2024
(2 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Dec 20, 2016 |
| New Dosing Schedule(D-156) | Jan 28, 2019 |
| New Dosing Schedule(D-157) | Jan 28, 2019 |
| Orphan Drug Exclusivity(ODE-308) | Dec 20, 2020 |
| New Indication(I-820) | Oct 18, 2022 |
| Orphan Drug Exclusivity(ODE-272) | Oct 18, 2026 |
Drugs and Companies using TREPROSTINIL DIOLAMINE ingredient
Market Authorisation Date: 20 December, 2013
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of ORENITRAM before it's drug patent expiration?
More Information on Dosage
ORENITRAM family patents
84. Oriahnn (copackaged) patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7056927 | ABBVIE | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
Sep, 2024
(a month from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 29, 2023 |
| New Chemical Entity Exclusivity(NCE) | Jul 23, 2023 |
NCE-1 date: 23 July, 2022
Market Authorisation Date: 29 May, 2020
Treatment: NA
Dosage: CAPSULE
How can I launch a generic of ORIAHNN (COPACKAGED) before it's drug patent expiration?
More Information on Dosage
ORIAHNN (COPACKAGED) family patents
85. Orilissa patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7056927 | ABBVIE | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
Sep, 2024
(a month from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 23, 2023 |
Drugs and Companies using ELAGOLIX SODIUM ingredient
NCE-1 date: 23 July, 2022
Market Authorisation Date: 23 July, 2018
Treatment: NA
Dosage: TABLET
How can I launch a generic of ORILISSA before it's drug patent expiration?
More Information on Dosage
ORILISSA family patents
86. Orserdu patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8399520 | STEMLINE THERAP | Selective estrogen receptor modulator |
Dec, 2024
(5 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 27, 2028 |
Drugs and Companies using ELACESTRANT DIHYDROCHLORIDE ingredient
NCE-1 date: 27 January, 2027
Market Authorisation Date: 27 January, 2023
Treatment: Treatment of an er-positive breast cancer
Dosage: TABLET
More Information on Dosage
ORSERDU family patents
87. Oxycontin patent expiration
OXYCONTIN's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8114383 | PURDUE PHARMA LP | Abuse-proofed dosage form |
Oct, 2024
(2 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-153) | Apr 16, 2016 |
| New Patient Population(NPP) | Aug 13, 2018 |
Drugs and Companies using OXYCODONE HYDROCHLORIDE ingredient
Market Authorisation Date: 05 April, 2010
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE
More Information on Dosage
OXYCONTIN family patents
88. Pepaxto patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6992207 | ONCOPEPTIDES AB | Melphalan derivatives and their use as cancer chemotherapeutic drugs |
Jun, 2024
(29 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 26, 2026 |
| Orphan Drug Exclusivity(ODE-348) | Feb 26, 2028 |
Drugs and Companies using MELPHALAN FLUFENAMIDE HYDROCHLORIDE ingredient
NCE-1 date: 26 February, 2025
Market Authorisation Date: 26 February, 2021
Treatment: In combination with dexamethasone to treat relapsed or refractory multiple myeloma (refactory to at least 1 proteasome inhibitor, 1 immunomodulatory agent, and 1 anti-cd38 mab) in adults who received ...
Dosage: POWDER
More Information on Dosage
PEPAXTO family patents
89. Ponvory patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE43728 | VANDA PHARMS INC | Thiazolidin-4-one derivatives |
Nov, 2024
(3 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9000018 | VANDA PHARMS INC | Thiazolidin-4-one-derivatives |
Nov, 2024
(3 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 18, 2026 |
Drugs and Companies using PONESIMOD ingredient
NCE-1 date: 18 March, 2025
Market Authorisation Date: 18 March, 2021
Treatment: Reduction of circulating lymphocytes in treating relapsing forms of multiple sclerosis (ms), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive dise...
Dosage: TABLET
More Information on Dosage
PONVORY family patents
90. Prevymis patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8513255 | MERCK SHARP DOHME | Substituted dihydroquinazolines |
May, 2024
(2 months ago) | |
| US7196086 | MERCK SHARP DOHME | Substituted dihydroquinazolines |
May, 2024
(2 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 08, 2022 |
| Orphan Drug Exclusivity(ODE-165) | Nov 08, 2024 |
| New Indication(I-916) | Jun 05, 2026 |
| New Dosing Schedule(D-189) | Aug 02, 2026 |
| Orphan Drug Exclusivity(ODE-423) | Jun 05, 2030 |
Drugs and Companies using LETERMOVIR ingredient
NCE-1 date: 08 November, 2021
Market Authorisation Date: 08 November, 2017
Treatment: NA
Dosage: TABLET; SOLUTION
More Information on Dosage
PREVYMIS family patents
91. Prezcobix patent expiration
PREZCOBIX's oppositions filed in EPO
PREZCOBIX IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8518987 | JANSSEN PRODS | Pseudopolymorphic forms of a HIV protease inhibitor |
Feb, 2024
(5 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8518987 (Pediatric) | JANSSEN PRODS | Pseudopolymorphic forms of a HIV protease inhibitor |
Aug, 2024
(22 days from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 27, 2017 |
Drugs and Companies using COBICISTAT; DARUNAVIR ingredient
NCE-1 date: 27 August, 2016
Market Authorisation Date: 29 January, 2015
Treatment: NA
Dosage: TABLET
How can I launch a generic of PREZCOBIX before it's drug patent expiration?
More Information on Dosage
PREZCOBIX family patents
92. Prezista patent expiration
PREZISTA's oppositions filed in EPO
PREZISTA IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8518987 | JANSSEN PRODS | Pseudopolymorphic forms of a HIV protease inhibitor |
Feb, 2024
(5 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8518987 (Pediatric) | JANSSEN PRODS | Pseudopolymorphic forms of a HIV protease inhibitor |
Aug, 2024
(22 days from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-578) | Oct 21, 2011 |
| New Dosing Schedule(D-118) | Oct 21, 2011 |
| New Dosing Schedule(D-119) | Dec 18, 2011 |
| New Strength(NS) | Dec 18, 2011 |
| New Dosing Schedule(D-129) | Dec 13, 2013 |
| Pediatric Exclusivity(PED) | Aug 01, 2016 |
| New Patient Population(NPP) | Dec 16, 2014 |
| New Dosing Schedule(D-135) | Feb 01, 2016 |
Drugs and Companies using DARUNAVIR ingredient
Market Authorisation Date: 18 December, 2008
Treatment: NA
Dosage: TABLET; SUSPENSION
How can I launch a generic of PREZISTA before it's drug patent expiration?
More Information on Dosage
PREZISTA family patents
93. Prialt patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9707270 | TERSERA | Method for administering ω-conopeptide |
Oct, 2024
(2 months from now) | |
| US8765680 | TERSERA | Method for administering omega-conopeptide |
Oct, 2024
(2 months from now) | |
| US8653033 | TERSERA | Method for administering omega-conopeptide |
Oct, 2024
(2 months from now) | |
Drugs and Companies using ZICONOTIDE ACETATE ingredient
Market Authorisation Date: 28 December, 2004
Treatment: Treatment of severe chronic pain via intrathecal infusion of ziconotide in patients also receiving morphine; Treatment of pain
Dosage: INJECTABLE
More Information on Dosage
PRIALT family patents
94. Protonix patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7553498 | WYETH PHARMS | Pantoprazole multiparticulate formulations |
Sep, 2024
(2 months from now) | |
| US7838027 | WYETH PHARMS | Pantoprazole multiparticulate formulations |
Sep, 2024
(2 months from now) | |
| US7550153 | WYETH PHARMS | Pantoprazole multiparticulate formulations |
Sep, 2024
(2 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-614) | Nov 12, 2012 |
| M(M-54) | Nov 12, 2012 |
| Pediatric Exclusivity(PED) | May 12, 2013 |
Drugs and Companies using PANTOPRAZOLE SODIUM ingredient
Market Authorisation Date: 14 November, 2007
Treatment: Erosive esophagitis, hypersecretory conditions including zollinger-ellison syndrome, maintenance of healing of erosive esophagitis and reduction of symptoms in patients with gerd
Dosage: FOR SUSPENSION, DELAYED RELEASE
How can I launch a generic of PROTONIX before it's drug patent expiration?
More Information on Dosage
PROTONIX family patents
95. Remodulin patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9713599 | UNITED THERAP | Parenteral formulations of treprostinil |
Dec, 2024
(4 months from now) | |
| US10076505 | UNITED THERAP | Inhalation formulations of Treprostinil |
Dec, 2024
(4 months from now) | |
| US10695308 | UNITED THERAP | Inhalation formulations of treprostinil |
Dec, 2024
(4 months from now) | |
Drugs and Companies using TREPROSTINIL ingredient
Market Authorisation Date: 28 September, 2023
Treatment: A method of treating pulmonary hypertension comprising parenterally administering a formulation comprising a) 0.1 to 5% w/v of treprostinil or a pharmaceutically acceptable salt thereof and b) a citra...
Dosage: INJECTABLE; SOLUTION
How can I launch a generic of REMODULIN before it's drug patent expiration?
More Information on Dosage
REMODULIN family patents
96. Restasis patent expiration
RESTASIS IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8629111 | ABBVIE | Methods of providing therapeutic effects using cyclosporin components |
Aug, 2024
(a month from now) | |
| US8642556 | ABBVIE | Methods of providing therapeutic effects using cyclosporin components |
Aug, 2024
(a month from now) | |
| US8633162 | ABBVIE | Methods of providing therapeutic effects using cyclosporin components |
Aug, 2024
(a month from now) | |
| US8685930 | ABBVIE | Methods of providing therapeutic effects using cyclosporin components |
Aug, 2024
(a month from now) | |
| US8648048 | ABBVIE | Methods of providing therapeutic effects using cyclosporin components |
Aug, 2024
(a month from now) | |
| US9248191 | ABBVIE | Methods of providing therapeutic effects using cyclosporin components |
Aug, 2024
(a month from now) | |
Drugs and Companies using CYCLOSPORINE ingredient
Market Authorisation Date: 23 December, 2002
Treatment: Increase tear production to treat patients with keratoconjunctivitis sicca (dry eye).; Increase tear production in patients with keratoconjunctivitis sicca (dry eye).
Dosage: EMULSION
How can I launch a generic of RESTASIS before it's drug patent expiration?
More Information on Dosage
RESTASIS family patents
97. Restasis Multidose patent expiration
RESTASIS MULTIDOSE IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8642556 | ABBVIE | Methods of providing therapeutic effects using cyclosporin components |
Aug, 2024
(a month from now) | |
| US8648048 | ABBVIE | Methods of providing therapeutic effects using cyclosporin components |
Aug, 2024
(a month from now) | |
| US9248191 | ABBVIE | Methods of providing therapeutic effects using cyclosporin components |
Aug, 2024
(a month from now) | |
| US8633162 | ABBVIE | Methods of providing therapeutic effects using cyclosporin components |
Aug, 2024
(a month from now) | |
| US8629111 | ABBVIE | Methods of providing therapeutic effects using cyclosporin components |
Aug, 2024
(a month from now) | |
| US8685930 | ABBVIE | Methods of providing therapeutic effects using cyclosporin components |
Aug, 2024
(a month from now) | |
Drugs and Companies using CYCLOSPORINE ingredient
Market Authorisation Date: 23 December, 2002
Treatment: Increase tear production in patients with keratoconjunctivitis sicca (dry eye).; Increase tear production to treat patients with keratoconjunctivitis sicca (dry eye).
Dosage: EMULSION
How can I launch a generic of RESTASIS MULTIDOSE before it's drug patent expiration?
More Information on Dosage
RESTASIS MULTIDOSE family patents
98. Revlimid patent expiration
REVLIMID's oppositions filed in EPO
Can you believe REVLIMID received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7855217 | BRISTOL MYERS SQUIBB | Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione |
Nov, 2024
(4 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Jun 05, 2020 |
| New Indication(I-672) | Jun 05, 2016 |
| New Strength(NS) | Jun 05, 2016 |
| New Indication(I-706) | Feb 17, 2018 |
| Orphan Drug Exclusivity(ODE-49) | Jun 05, 2020 |
| Orphan Drug Exclusivity(ODE-88) | Feb 17, 2022 |
| New Indication(I-796) | May 28, 2022 |
| New Indication(I-797) | May 28, 2022 |
| Orphan Drug Exclusivity(ODE-131) | Feb 22, 2024 |
| Orphan Drug Exclusivity(ODE-245) | May 28, 2026 |
| Orphan Drug Exclusivity(ODE-241) | May 28, 2026 |
Drugs and Companies using LENALIDOMIDE ingredient
Market Authorisation Date: 21 December, 2011
Treatment: NA
Dosage: CAPSULE
How can I launch a generic of REVLIMID before it's drug patent expiration?
More Information on Dosage
REVLIMID family patents
99. Rhofade patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8420688 | MAYNE PHARMA | Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists |
Aug, 2024
(8 days from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jan 18, 2020 |
Drugs and Companies using OXYMETAZOLINE HYDROCHLORIDE ingredient
Market Authorisation Date: 18 January, 2017
Treatment: Topical treatment of persistent facial erythema associated with rosacea in adults with 1% oxymetazoline hydrochloride cream
Dosage: CREAM
How can I launch a generic of RHOFADE before it's drug patent expiration?
More Information on Dosage
RHOFADE family patents
100. Rytelo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9388416 | GERON | Modified oligonucleotides for telomerase inhibition |
Sep, 2024
(a month from now) | |
| US9388415 | GERON | Modified oligonucleotides for telomerase inhibition |
Sep, 2024
(a month from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-482) | Jun 06, 2031 |
Drugs and Companies using IMETELSTAT SODIUM ingredient
Market Authorisation Date: 06 June, 2024
Treatment: Treatment of patients with myelodysplastic syndromes (mds) with transfusion-dependent anemia
Dosage: POWDER
More Information on Dosage
RYTELO family patents
101. Sanctura Xr patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7763635 | ALLERGAN | Once daily dosage forms of trospium |
Nov, 2024
(3 months from now) | |
| US7759359 | ALLERGAN | Method of treating bladder dysfunction with once-a-day trospium salt formulation |
Nov, 2024
(3 months from now) | |
| US7781449 | ALLERGAN | Trospium chloride treatment method |
Nov, 2024
(3 months from now) | |
| US7781448 | ALLERGAN | Once daily dosage forms of trospium |
Nov, 2024
(3 months from now) | |
Drugs and Companies using TROSPIUM CHLORIDE ingredient
Market Authorisation Date: 03 August, 2007
Treatment: Method of treating bladder dysfunction with once a day trospium salt formulation
Dosage: CAPSULE, EXTENDED RELEASE
How can I launch a generic of SANCTURA XR before it's drug patent expiration?
More Information on Dosage
SANCTURA XR family patents
102. Saxenda patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7762994 (Pediatric) | NOVO | Needle mounting system and a method for mounting a needle assembly |
Nov, 2024
(3 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 25, 2015 |
| New Product(NP) | Jan 25, 2017 |
| New Patient Population(NPP) | Dec 04, 2023 |
Drugs and Companies using LIRAGLUTIDE ingredient
NCE-1 date: 25 January, 2014
Market Authorisation Date: 23 December, 2014
Treatment: NA
Dosage: SOLUTION
How can I launch a generic of SAXENDA before it's drug patent expiration?
More Information on Dosage
SAXENDA family patents
103. Soliqua 100/33 patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9604009 | SANOFI-AVENTIS US | Drive mechanisms suitable for use in drug delivery devices |
Aug, 2024
(22 days from now) | |
| US9533105 | SANOFI-AVENTIS US | Drive mechanisms suitable for use in drug delivery devices |
Aug, 2024
(23 days from now) | |
| US9623189 | SANOFI-AVENTIS US | Relating to drive mechanisms suitable for use in drug delivery devices |
Aug, 2024
(25 days from now) | |
| US9561331 | SANOFI-AVENTIS US | Drive mechanisms suitable for use in drug delivery devices |
Aug, 2024
(a month from now) | |
| US8512297 | SANOFI-AVENTIS US | Pen-type injector |
Sep, 2024
(a month from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Nov 21, 2019 |
| New Chemical Entity Exclusivity(NCE) | Jul 27, 2021 |
Drugs and Companies using INSULIN GLARGINE; LIXISENATIDE ingredient
NCE-1 date: 27 July, 2020
Market Authorisation Date: 21 November, 2016
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
SOLIQUA 100/33 family patents
104. Spiriva Respimat patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7284474 | BOEHRINGER INGELHEIM | Piston-pumping system having o-ring seal properties |
Aug, 2024
(a month from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 15, 2018 |
| New Patient Population(NPP) | Feb 15, 2020 |
| Pediatric Exclusivity(PED) | Aug 15, 2020 |
Drugs and Companies using TIOTROPIUM BROMIDE ingredient
Market Authorisation Date: 15 September, 2015
Treatment: NA
Dosage: SPRAY, METERED
How can I launch a generic of SPIRIVA RESPIMAT before it's drug patent expiration?
More Information on Dosage
SPIRIVA RESPIMAT family patents
105. Stiolto Respimat patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7284474 | BOEHRINGER INGELHEIM | Piston-pumping system having o-ring seal properties |
Aug, 2024
(a month from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | May 21, 2018 |
| M(M-173) | Mar 18, 2019 |
| New Chemical Entity Exclusivity(NCE) | Jul 31, 2019 |
| M(M-233) | Oct 05, 2021 |
Drugs and Companies using OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE ingredient
NCE-1 date: 31 July, 2018
Market Authorisation Date: 21 May, 2015
Treatment: NA
Dosage: SPRAY, METERED
More Information on Dosage
STIOLTO RESPIMAT family patents
106. Striverdi Respimat patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7284474 | BOEHRINGER INGELHEIM | Piston-pumping system having o-ring seal properties |
Aug, 2024
(a month from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 31, 2019 |
Drugs and Companies using OLODATEROL HYDROCHLORIDE ingredient
NCE-1 date: 31 July, 2018
Market Authorisation Date: 31 July, 2014
Treatment: NA
Dosage: SPRAY, METERED
More Information on Dosage
STRIVERDI RESPIMAT family patents
107. Sumavel Dosepro patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8287489 | ENDO OPERATIONS | Device for readying a needle free injector for delivery |
Dec, 2024
(4 months from now) | |
Drugs and Companies using SUMATRIPTAN SUCCINATE ingredient
Market Authorisation Date: 26 November, 2013
Treatment: NA
Dosage: INJECTABLE
More Information on Dosage
SUMAVEL DOSEPRO family patents
108. Sustol patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10357570 | HERON THERAPS INC | Methods of treating nausea utilizing semi-solid delivery vehicle compositions comprising granisetron |
Sep, 2024
(2 months from now) | |
| US8252305 | HERON THERAPS INC | Methods of treating emesis utilizing semi-solid delivery pharmaceutical compositions comprising granisetron |
Sep, 2024
(2 months from now) | |
| US8715710 | HERON THERAPS INC | Semi-solid delivery vehicle and pharmaceutical compositions for delivery of granisetron |
Sep, 2024
(2 months from now) | |
| US8252304 | HERON THERAPS INC | Semi-solid delivery vehicle and pharmaceutical compositions for delivery of granisetron |
Sep, 2024
(2 months from now) | |
| US9913910 | HERON THERAPS INC | Methods of treating nausea utilizing semi-solid delivery vehicle compositions comprising granisetron |
Sep, 2024
(2 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Aug 09, 2019 |
Drugs and Companies using GRANISETRON ingredient
Market Authorisation Date: 09 August, 2016
Treatment: Prophylactic treatment of nausea and vomiting, including prevention of acute and delayed nausea and vomiting associated chemotherapy; Treatment or prevention of nausea and vomiting
Dosage: INJECTION, EXTENDED RELEASE
More Information on Dosage
SUSTOL family patents
109. Symbicort patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8875699 | ASTRAZENECA | Inhaler cap strap |
Nov, 2024
(3 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-582) | Feb 27, 2012 |
| New Patient Population(NPP) | Jan 27, 2020 |
| Pediatric Exclusivity(PED) | Jul 27, 2020 |
| M(M-210) | Sep 11, 2020 |
| M(M-214) | Dec 20, 2020 |
Drugs and Companies using BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE ingredient
Market Authorisation Date: 21 July, 2006
Treatment: NA
Dosage: AEROSOL, METERED
How can I launch a generic of SYMBICORT before it's drug patent expiration?
More Information on Dosage
SYMBICORT family patents
110. Symtuza patent expiration
SYMTUZA's oppositions filed in EPO
SYMTUZA IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8518987 | JANSSEN PRODS | Pseudopolymorphic forms of a HIV protease inhibitor |
Feb, 2024
(5 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 05, 2020 |
| New Combination(NC) | Jul 17, 2021 |
NCE-1 date: 06 November, 2019
Market Authorisation Date: 17 July, 2018
Treatment: NA
Dosage: TABLET
How can I launch a generic of SYMTUZA before it's drug patent expiration?
More Information on Dosage
SYMTUZA family patents
111. Technivie patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8268349 | ABBVIE | Solid pharmaceutical dosage form |
Aug, 2024
(a month from now) | |
| US8399015 | ABBVIE | Solid pharmaceutical dosage form |
Aug, 2024
(a month from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jul 24, 2018 |
| New Indication(I-743) | Jul 24, 2018 |
| New Chemical Entity Exclusivity(NCE) | Dec 19, 2019 |
Drugs and Companies using OMBITASVIR; PARITAPREVIR; RITONAVIR ingredient
NCE-1 date: 19 December, 2018
Market Authorisation Date: 24 July, 2015
Treatment: NA
Dosage: TABLET
More Information on Dosage
TECHNIVIE family patents
112. Tobi Podhaler patent expiration
TOBI PODHALER's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8069851 | MYLAN SPECIALITY LP | Aeorosolization apparatus with air inlet shield |
Sep, 2024
(2 months from now) | |
| US11484671 | MYLAN SPECIALITY LP | Aerosolization apparatus with capsule puncture alignment guide |
Nov, 2024
(3 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 22, 2016 |
Drugs and Companies using TOBRAMYCIN ingredient
Market Authorisation Date: 22 March, 2013
Treatment: Treatment of cystic fibrosis patients with pseudomonas aeruginosa
Dosage: POWDER
More Information on Dosage
TOBI PODHALER family patents
113. Toujeo Max Solostar patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9604009 | SANOFI US SERVICES | Drive mechanisms suitable for use in drug delivery devices |
Aug, 2024
(22 days from now) | |
| US9533105 | SANOFI US SERVICES | Drive mechanisms suitable for use in drug delivery devices |
Aug, 2024
(23 days from now) | |
| US9623189 | SANOFI US SERVICES | Relating to drive mechanisms suitable for use in drug delivery devices |
Aug, 2024
(25 days from now) | |
| US9561331 | SANOFI US SERVICES | Drive mechanisms suitable for use in drug delivery devices |
Aug, 2024
(a month from now) | |
| US8512297 | SANOFI US SERVICES | Pen-type injector |
Sep, 2024
(a month from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Feb 25, 2018 |
| New Patient Population(NPP) | Nov 26, 2022 |
Drugs and Companies using INSULIN GLARGINE RECOMBINANT ingredient
Market Authorisation Date: 25 February, 2015
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
TOUJEO MAX SOLOSTAR family patents
114. Toujeo Solostar patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9604009 | SANOFI US SERVICES | Drive mechanisms suitable for use in drug delivery devices |
Aug, 2024
(22 days from now) | |
| US9533105 | SANOFI US SERVICES | Drive mechanisms suitable for use in drug delivery devices |
Aug, 2024
(23 days from now) | |
| US9623189 | SANOFI US SERVICES | Relating to drive mechanisms suitable for use in drug delivery devices |
Aug, 2024
(25 days from now) | |
| US9561331 | SANOFI US SERVICES | Drive mechanisms suitable for use in drug delivery devices |
Aug, 2024
(a month from now) | |
| US8512297 | SANOFI US SERVICES | Pen-type injector |
Sep, 2024
(a month from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Feb 25, 2018 |
| New Patient Population(NPP) | Nov 26, 2022 |
Drugs and Companies using INSULIN GLARGINE RECOMBINANT ingredient
Market Authorisation Date: 25 February, 2015
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
TOUJEO SOLOSTAR family patents
115. Tpoxx patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8124643 | SIGA TECHNOLOGIES | Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases |
Jun, 2024
(a month ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 13, 2023 |
| Orphan Drug Exclusivity(ODE-200) | Jul 13, 2025 |
Drugs and Companies using TECOVIRIMAT ingredient
NCE-1 date: 13 July, 2022
Market Authorisation Date: 13 July, 2018
Treatment: NA
Dosage: CAPSULE; SOLUTION
More Information on Dosage
TPOXX family patents
116. Tukysa patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7452895 | SEAGEN | Quinazoline analogs as receptor tyrosine kinase inhibitors |
Nov, 2024
(3 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 17, 2025 |
| New Indication(I-906) | Jan 19, 2026 |
| Orphan Drug Exclusivity(ODE-309) | Apr 17, 2027 |
| Orphan Drug Exclusivity(ODE-422) | Jan 19, 2030 |
Drugs and Companies using TUCATINIB ingredient
NCE-1 date: 17 April, 2024
Market Authorisation Date: 17 April, 2020
Treatment: Treatment of breast cancer including her2 (erbb2)-positive or -overexpressing breast cancer
Dosage: TABLET
More Information on Dosage
TUKYSA family patents
117. Vandazole patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7456207 | TEVA PHARMS | Vaginal pharmaceutical compositions and methods for preparing them |
Sep, 2024
(a month from now) | |
Drugs and Companies using METRONIDAZOLE ingredient
Market Authorisation Date: 20 May, 2005
Treatment: NA
Dosage: GEL
More Information on Dosage
VANDAZOLE family patents
118. Varithena patent expiration
VARITHENA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7731986 | PROVENSIS | Therapeutic foam |
Nov, 2024
(3 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8122917 | PROVENSIS | Apparatus and method for dispensing foam |
Sep, 2024
(a month from now) | |
Drugs and Companies using POLIDOCANOL ingredient
Market Authorisation Date: 21 December, 2017
Treatment: A method of intravenous injection using ultrasound guidance, administered via a single cannula into the lumen of the target incompetent trunk veins or by direct injection into varicosities
Dosage: SOLUTION
More Information on Dosage
VARITHENA family patents
119. Veramyst patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9320862 | GLAXOSMITHKLINE | Fluid dispensing device |
Nov, 2024
(3 months from now) | |
Drugs and Companies using FLUTICASONE FUROATE ingredient
Market Authorisation Date: 02 August, 2016
Treatment: NA
Dosage: SPRAY, METERED
More Information on Dosage
VERAMYST family patents
120. Victoza patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7762994 (Pediatric) | NOVO NORDISK INC | Needle mounting system and a method for mounting a needle assembly |
Nov, 2024
(3 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 25, 2015 |
| M(M-115) | Apr 06, 2015 |
| M(M-176) | Apr 22, 2019 |
| New Indication(I-750) | Aug 25, 2020 |
| New Patient Population(NPP) | Jun 17, 2022 |
| Pediatric Exclusivity(PED) | Dec 17, 2022 |
Drugs and Companies using LIRAGLUTIDE ingredient
NCE-1 date: 17 December, 2021
Market Authorisation Date: 25 January, 2010
Treatment: NA
Dosage: SOLUTION
How can I launch a generic of VICTOZA before it's drug patent expiration?
More Information on Dosage
VICTOZA family patents
121. Victrelis patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE43298 | MERCK SHARP DOHME | Peptides as NS3-serine protease inhibitors of hepatitis C virus |
Dec, 2024
(4 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Feb 13, 2016 |
| M(M-126) | Feb 27, 2016 |
| New Chemical Entity Exclusivity(NCE) | May 13, 2016 |
Drugs and Companies using BOCEPREVIR ingredient
NCE-1 date: 14 May, 2015
Market Authorisation Date: 13 May, 2011
Treatment: Treatment of chronic hepatitis c (chc) genotype 1 infection in combination with peginterferon alfa and ribavirin in adult patients (>=18 years of age) with compensated liver disease
Dosage: CAPSULE
More Information on Dosage
VICTRELIS family patents
122. Viekira Pak (copackaged) patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8399015 | ABBVIE | Solid pharmaceutical dosage form |
Aug, 2024
(a month from now) | |
| US8268349 | ABBVIE | Solid pharmaceutical dosage form |
Aug, 2024
(a month from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-163) | Apr 22, 2019 |
| New Chemical Entity Exclusivity(NCE) | Dec 19, 2019 |
Drugs and Companies using DASABUVIR SODIUM; OMBITASVIR, PARITAPREVIR, RITONAVIR ingredient
NCE-1 date: 19 December, 2018
Market Authorisation Date: 19 December, 2014
Treatment: NA
Dosage: TABLET
More Information on Dosage
VIEKIRA PAK (COPACKAGED) family patents
123. Viekira Xr patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8399015 | ABBVIE | Solid pharmaceutical dosage form |
Aug, 2024
(a month from now) | |
| US8268349 | ABBVIE | Solid pharmaceutical dosage form |
Aug, 2024
(a month from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 19, 2019 |
Drugs and Companies using DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR ingredient
NCE-1 date: 19 December, 2018
Market Authorisation Date: 22 July, 2016
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE
More Information on Dosage
VIEKIRA XR family patents
124. Vizamyl patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8236282 | GE HEALTHCARE | Benzothiazole derivative compounds, compositions and uses |
May, 2024
(2 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 25, 2018 |
Drugs and Companies using FLUTEMETAMOL F-18 ingredient
NCE-1 date: 25 October, 2017
Market Authorisation Date: 25 October, 2013
Treatment: NA
Dosage: INJECTABLE
More Information on Dosage
VIZAMYL family patents
125. Vyndamax patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7214695 | FOLDRX PHARMS | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding |
Dec, 2024
(4 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7214696 | FOLDRX PHARMS | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding |
Dec, 2024
(4 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 03, 2024 |
| Orphan Drug Exclusivity(ODE-237) | May 03, 2026 |
Drugs and Companies using TAFAMIDIS ingredient
NCE-1 date: 04 May, 2023
Market Authorisation Date: 03 May, 2019
Treatment: Treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis (attr-cm)
Dosage: CAPSULE
How can I launch a generic of VYNDAMAX before it's drug patent expiration?
More Information on Dosage
VYNDAMAX family patents
126. Vyndaqel patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7214695 | FOLDRX PHARMS | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding |
Dec, 2024
(4 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7214696 | FOLDRX PHARMS | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding |
Dec, 2024
(4 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 03, 2024 |
| Orphan Drug Exclusivity(ODE-237) | May 03, 2026 |
Drugs and Companies using TAFAMIDIS MEGLUMINE ingredient
NCE-1 date: 04 May, 2023
Market Authorisation Date: 03 May, 2019
Treatment: Treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis (attr-cm)
Dosage: CAPSULE
More Information on Dosage
VYNDAQEL family patents
127. Xarelto patent expiration
XARELTO's oppositions filed in EPO
XARELTO IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7157456 | JANSSEN PHARMS | Substituted oxazolidinones and their use in the field of blood coagulation |
Aug, 2024
(a month from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9415053 | JANSSEN PHARMS | Solid, orally administrable pharmaceutical composition |
Nov, 2024
(3 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-643) | Nov 04, 2014 |
| New Indication(I-662) | Nov 02, 2015 |
| New Indication(I-660) | Nov 02, 2015 |
| New Indication(I-661) | Nov 02, 2015 |
| New Chemical Entity Exclusivity(NCE) | Jul 01, 2016 |
| New Dosing Schedule(D-168) | Oct 27, 2020 |
| New Indication(I-824) | Oct 11, 2021 |
| New Indication(I-810) | Oct 11, 2022 |
| M(M-284) | Mar 10, 2023 |
| New Indication(I-867) | Aug 23, 2024 |
| Pediatric Exclusivity(PED) | Feb 23, 2025 |
Drugs and Companies using RIVAROXABAN ingredient
NCE-1 date: 24 February, 2024
Market Authorisation Date: 11 October, 2018
Treatment: Reduction of risk of major thrombotic vascular events (myocardial infarction, ischemic stroke, acute limb ischemia, and major amputation of vascular etiology) in patients with pad; Treatment of deep v...
Dosage: TABLET; FOR SUSPENSION
How can I launch a generic of XARELTO before it's drug patent expiration?
More Information on Dosage
XARELTO family patents
128. Xeglyze patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9839631 | HATCHTECH | Methods and compositions for controlling ectoparasites |
Jul, 2024
(8 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 24, 2025 |
Drugs and Companies using ABAMETAPIR ingredient
NCE-1 date: 24 July, 2024
Market Authorisation Date: 24 July, 2020
Treatment: Topical treatment of head lice infestation in patients 6 months of age and older
Dosage: LOTION
More Information on Dosage
XEGLYZE family patents
129. Xifaxan patent expiration
XIFAXAN's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8835452 | SALIX PHARMS | Polymorphic forms α, β and γ of rifaximin |
Jun, 2024
(a month ago) | |
| US7612199 | SALIX PHARMS | Polymorphic forms α, β, and γ of rifaximin |
Jun, 2024
(a month ago) | |
| US7045620 | SALIX PHARMS | Polymorphous forms of rifaximin, processes for their production and use thereof in medicinal preparations |
Jun, 2024
(a month ago) | |
| US7902206 | SALIX PHARMS | Polymorphic forms α, β and γ of rifaximin |
Jun, 2024
(a month ago) | |
| US8158781 | SALIX PHARMS | Polymorphic forms α, β and γ of rifaximin |
Jun, 2024
(a month ago) | |
Drugs and Companies using RIFAXIMIN ingredient
Market Authorisation Date: 25 May, 2004
Treatment: NA
Dosage: TABLET
How can I launch a generic of XIFAXAN before it's drug patent expiration?
More Information on Dosage
XIFAXAN family patents
130. Xiidra patent expiration
Can you believe XIIDRA received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7928122 | BAUSCH AND LOMB INC | Modulators of cellular adhesion |
Nov, 2024
(3 months from now) | |
| US7745460 | BAUSCH AND LOMB INC | Modulators of cellular adhesion |
Nov, 2024
(3 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9216174 | BAUSCH AND LOMB INC | Modulators of cellular adhesion |
Nov, 2024
(3 months from now) | |
| US10124000 | BAUSCH AND LOMB INC | Modulators of cellular adhesion |
Nov, 2024
(3 months from now) | |
| US7790743 | BAUSCH AND LOMB INC | Modulators of cellular adhesion |
Nov, 2024
(3 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 11, 2021 |
Drugs and Companies using LIFITEGRAST ingredient
NCE-1 date: 11 July, 2020
Market Authorisation Date: 11 July, 2016
Treatment: Treatment of the signs and symptoms of dry eye disease (ded); Treatment of signs and symptoms of dry eye disease (ded)
Dosage: SOLUTION/DROPS
How can I launch a generic of XIIDRA before it's drug patent expiration?
More Information on Dosage
XIIDRA family patents
131. Xopenex Hfa patent expiration
XOPENEX HFA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7256310 | LUPIN | Levalbuterol salt |
Oct, 2024
(2 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-156) | Mar 12, 2018 |
Drugs and Companies using LEVALBUTEROL TARTRATE ingredient
Market Authorisation Date: 11 March, 2005
Treatment: Treatment or prevention of bronchospasm or asthmatic symptoms
Dosage: AEROSOL, METERED
How can I launch a generic of XOPENEX HFA before it's drug patent expiration?
More Information on Dosage
XOPENEX HFA family patents
132. Xultophy 100/3.6 patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7762994 (Pediatric) | NOVO | Needle mounting system and a method for mounting a needle assembly |
Nov, 2024
(3 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Nov 21, 2019 |
| New Chemical Entity Exclusivity(NCE) | Sep 25, 2020 |
| M(M-242) | Aug 08, 2022 |
Drugs and Companies using INSULIN DEGLUDEC; LIRAGLUTIDE ingredient
NCE-1 date: 26 September, 2019
Market Authorisation Date: 21 November, 2016
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
XULTOPHY 100/3.6 family patents
133. Xyrem patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7668730 (Pediatric) | JAZZ PHARMS | Sensitive drug distribution system and method |
Dec, 2024
(4 months from now) | |
|
US7765106 (Pediatric) | JAZZ PHARMS | Sensitive drug distribution system and method |
Dec, 2024
(4 months from now) | |
|
US7765107 (Pediatric) | JAZZ PHARMS | Sensitive drug distribution system and method |
Dec, 2024
(4 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Nov 18, 2012 |
| New Patient Population(NPP) | Oct 26, 2021 |
| Orphan Drug Exclusivity(ODE-231) | Oct 26, 2025 |
| Pediatric Exclusivity(PED) | Apr 26, 2026 |
Drugs and Companies using SODIUM OXYBATE ingredient
Market Authorisation Date: 17 July, 2002
Treatment: NA
Dosage: SOLUTION
How can I launch a generic of XYREM before it's drug patent expiration?
More Information on Dosage
XYREM family patents
134. Zavzpret patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7220862 | PFIZER | Calcitonin gene related peptide receptor antagonists |
Jan, 2024
(6 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 09, 2028 |
Drugs and Companies using ZAVEGEPANT HYDROCHLORIDE ingredient
NCE-1 date: 10 March, 2027
Market Authorisation Date: 09 March, 2023
Treatment: NA
Dosage: SPRAY, METERED
More Information on Dosage
ZAVZPRET family patents
135. Zokinvy patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7838531 | SENTYNL THERAPS INC | Farnesyltransferase inhibitors for treatment of laminopathies, cellular aging and atherosclerosis |
Jul, 2024
(a day from now) | |
| US8828356 | SENTYNL THERAPS INC | Farnesyltransferase inhibitors for treatment of laminopathies, cellular aging and atherosclerosis |
Oct, 2024
(2 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 20, 2025 |
| Orphan Drug Exclusivity(ODE-324) | Nov 20, 2027 |
Drugs and Companies using LONAFARNIB ingredient
NCE-1 date: 20 November, 2024
Market Authorisation Date: 20 November, 2020
Treatment: Reducing the risk of mortality in hutchinson-gilford progeria syndrome (hgps)
Dosage: CAPSULE
More Information on Dosage
ZOKINVY family patents
136. Zontivity patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7713999 | KEY THERAP | Thrombin receptor antagonists |
May, 2024
(a month ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 08, 2019 |
Drugs and Companies using VORAPAXAR SULFATE ingredient
NCE-1 date: 08 May, 2018
Market Authorisation Date: 08 May, 2014
Treatment: Reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction (mi) or with peripheral arterial disease (pad)
Dosage: TABLET
More Information on Dosage
ZONTIVITY family patents
List of large molecules
1. List of Cimzia large molecules
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| US7012135 | NA | NA |
Feb, 2024
(5 months ago) |
2. List of Elelyso large molecules
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| US8227230 | NA | NA |
Feb, 2024
(4 months ago) |
3. List of Aranesp large molecules
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| US7217689 | NA | NA |
May, 2024
(2 months ago) |
4. List of Avastin large molecules
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| US9795672 | GENENTECH, INC. | Treatment with anti-VEGF antibodies |
May, 2024
(a month ago) |
Ingredients: BEVACIZUMAB
5. List of Adcetris large molecules
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| US7829531 | NA | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
Jun, 2024
(a month ago) |
Ingredients: BRENTUXIMAB
6. List of Tysabri large molecules
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| US7759117 | BIOGEN INC. | Use of depth filtration in series with continuous centrifugation to clarify mammalian cell cultures |
Jun, 2024
(a month ago) | |
| US7157276 | BIOGEN INC. | Use of depth filtration in series with continuous centrifugation to clarify mammalian cell cultures |
Jun, 2024
(a month ago) |
Ingredients: NATALIZUMAB
7. List of Fasenra large molecules
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| US7718175 | NA | Method of modulating the activity of functional immune molecules to interleukin-5 receptor protein |
Jul, 2024
(18 days ago) |
Ingredients: BENRALIZUMAB
8. List of Simponi large molecules
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| US7691378 | NA | NA |
Sep, 2024
(a month from now) |